These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 8946870)
1. "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer. Hoskins PJ; Swenerton KD; Pike JA; McMurtrie EM; Lee N Gynecol Oncol; 1996 Dec; 63(3):345-51. PubMed ID: 8946870 [TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
3. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477 [TBL] [Abstract][Full Text] [Related]
5. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925 [TBL] [Abstract][Full Text] [Related]
9. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657 [TBL] [Abstract][Full Text] [Related]
14. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S; Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496 [TBL] [Abstract][Full Text] [Related]
15. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S J BUON; 2009; 14(2):203-9. PubMed ID: 19650167 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer]. Li DX; Chen XB Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023 [TBL] [Abstract][Full Text] [Related]
18. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142 [TBL] [Abstract][Full Text] [Related]